Sequential Afatinib and Osimertinib in Asian Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer and Acquired T790M: Combined Analysis of Two Global Non-Interventional Studies-Reference-Cited by-同舟云学术

Sequential Afatinib and Osimertinib in Asian Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer and Acquired T790M: Combined Analysis of Two Global Non-Interventional Studies

Published:2022-08 Issue: Volume:Volume 15 Page:873-882
ISSN:1178-6930
Container-title:OncoTargets and Therapy
language:en
Short-container-title:OTT

Author:

Miura Satoru,Jung Hyun Ae,Lee Shin Yup,Lee Seung Hyeun^ORCID,Lee Min Ki,Lee Yong Chul,Hochmair Maximilian J,Yang Cheng-Ta^ORCID,Märten Angela,Yang James Chih-Hsin^ORCID,Popat Sanjay

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Oncology

Reference27 articles.

1. Osimertinib in UntreatedEGFR-Mutated Advanced Non–Small-Cell Lung Cancer

2. EGFR tyrosine kinase inhibitors for EGFR mutation-positive non-small-cell lung cancer: outcomes in Asian populations

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The difference between dacomitinib and afatinib in effectiveness and safety in first-line treatment of patients with advanced EGFR-mutant non-small cell lung cancer: a real-world observational study;BMC Cancer;2024-02-19

2. A real-world cohort study of first-line afatinib in patients with EGFR-mutant advanced non-small cell lung cancer in Vietnam;BMC Cancer;2024-02-05

3. Differential prognostic value of tumor and plasma T790M mutations in EGFR TKI-treated advanced NSCLC;Therapeutic Advances in Medical Oncology;2024-01

4. Significance of micro-EGFR T790M mutations on EGFR-tyrosine kinase inhibitor efficacy in non-small cell lung cancer;Scientific Reports;2023-11-13

5. Final Report on Real-World Effectiveness of Sequential Afatinib and Osimertinib in EGFR-Positive Advanced Non–Small Cell Lung Cancer: Updated Analysis of the RESET Study;Cancer Research and Treatment;2023-10-15